STOCK TITAN

[Form 4] VolitionRX Limited Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Gael Forterre, Chief Commercial Officer of VolitionRx Limited (VNRX), was awarded 9,727 restricted stock units (RSUs) on August 15, 2025 in lieu of cash compensation. The RSUs are payable in shares upon settlement and will be earned in six approximately equal monthly installments beginning September 1, 2025. Once earned, the RSUs remain subject to additional time-based vesting in two installments of 4,864 units on November 1, 2025 and 4,863 units on February 1, 2026, and require continued service for each applicable earning and vesting date.

Following the award, Mr. Forterre directly beneficially owns 166,427 shares and indirectly holds 5,000 shares through his spouse and 32,500 shares managed by Armorica Partners, LLC, of which he is the managing director and sole shareholder; he disclaims beneficial ownership except for pecuniary interest.

Gael Forterre, Chief Commercial Officer di VolitionRx Limited (VNRX), ha ricevuto 9.727 unità azionarie soggette a restrizioni (RSU) in data 15 agosto 2025 in sostituzione della retribuzione in contanti. Le RSU saranno corrisposte in azioni al momento della liquidazione e verranno maturate in sei rate mensili approssimativamente uguali a partire dal 1° settembre 2025. Una volta maturate, le RSU resteranno soggette a un ulteriore periodo di vesting basato sul tempo, in due tranche di 4.864 unità il 1° novembre 2025 e 4.863 unità il 1° febbraio 2026, richiedendo la continuazione del servizio per ciascuna data di maturazione e di vesting applicabile.

In seguito all'assegnazione, il Sig. Forterre detiene direttamente 166.427 azioni e possiede indirettamente 5.000 azioni tramite la coniuge e 32.500 azioni gestite da Armorica Partners, LLC, di cui è managing director e unico azionista; egli rinuncia a qualsiasi prelazione di proprietà effettiva fatta eccezione per l'interesse patrimoniale.

Gael Forterre, Chief Commercial Officer de VolitionRx Limited (VNRX), recibió 9.727 unidades de acciones restringidas (RSU) el 15 de agosto de 2025 en lugar de una compensación en efectivo. Las RSU se pagarán en acciones al momento del ajuste y se devengarán en seis cuotas mensuales aproximadamente iguales a partir del 1 de septiembre de 2025. Una vez devengadas, las RSU seguirán sujetas a un período adicional de adquisición basado en el tiempo, en dos cuotas de 4.864 unidades el 1 de noviembre de 2025 y 4.863 unidades el 1 de febrero de 2026, requiriendo la continuidad del servicio para cada fecha de devengo y adquisición aplicable.

Tras la concesión, el Sr. Forterre posee directamente 166.427 acciones e indirectamente 5.000 acciones a través de su cónyuge y 32.500 acciones gestionadas por Armorica Partners, LLC, de la que es director gerente y único accionista; él renuncia a la propiedad beneficiaria salvo por el interés pecuniario.

VolitionRx Limited(VNRX)의 Chief Commercial Officer인 Gael Forterre는 현금 보수 대신 2025년 8월 15일에 9,727개의 제한부 주식 단위(RSU)를 부여받았습니다. RSU는 결제 시 주식으로 지급되며 2025년 9월 1일부터 시작해 약 여섯 번의 동일한 월별 분할로 취득됩니다. 취득된 후에도 RSU는 추가적인 시간 기반 베스팅 대상이며 2025년 11월 1일에 4,864단위, 2026년 2월 1일에 4,863단위의 두 차례로 나뉘어 베스팅되며 각 취득 및 베스팅 날짜에 대해 계속 근무해야 합니다.

수여 이후 Forterre 씨는 직접적으로 166,427주를 보유하고 있으며 배우자를 통해 5,000주를 간접 보유하고, 그가 전무이사이자 유일한 주주인 Armorica Partners, LLC가 관리하는 32,500주를 보유하고 있습니다; 그는 금전적 이익을 제외한 실질적 소유권을 부인합니다.

Gael Forterre, Chief Commercial Officer de VolitionRx Limited (VNRX), s'est vu attribuer 9 727 unités d'actions restreintes (RSU) le 15 août 2025 en lieu et place d'une rémunération en espèces. Les RSU seront réglées en actions à la liquidation et seront acquises en six versements mensuels à peu près égaux à compter du 1er septembre 2025. Une fois acquises, elles resteront soumises à un vesting supplémentaire fondé sur le temps, en deux tranches de 4 864 unités le 1er novembre 2025 et 4 863 unités le 1er février 2026, et requièrent la poursuite du service pour chaque date d'acquisition et de vesting applicable.

Après l'attribution, M. Forterre détient directement 166 427 actions et détient indirectement 5 000 actions par l'intermédiaire de son conjoint et 32 500 actions gérées par Armorica Partners, LLC, dont il est le directeur général et l'unique actionnaire ; il décline toute qualité de propriétaire bénéficiaire, sauf pour l'intérêt pécuniaire.

Gael Forterre, Chief Commercial Officer von VolitionRx Limited (VNRX), wurde am 15. August 2025 statt einer Barvergütung 9.727 Restricted Stock Units (RSUs) zugeteilt. Die RSUs werden bei Abwicklung in Aktien ausgezahlt und werden in sechs annähernd gleichen monatlichen Raten ab dem 1. September 2025 verdient. Nach dem Erwerb unterliegen die RSUs weiterhin einer zeitlich gestaffelten Vesting-Regelung in zwei Tranchen von 4.864 Einheiten am 1. November 2025 und 4.863 Einheiten am 1. Februar 2026 und setzen für jedes relevante Earn- und Vesting-Datum fortgesetzte Dienstleistung voraus.

Nach der Zuteilung besitzt Herr Forterre direkt 166.427 Aktien und hält indirekt 5.000 Aktien über seine Ehefrau sowie 32.500 Aktien, die von Armorica Partners, LLC verwaltet werden, deren Geschäftsführer und Alleingesellschafter er ist; er weist eine nennenswerte wirtschaftliche Eigentümerschaft außer seinem geldwerten Interesse zurück.

Positive
  • RSU grant of 9,727 units awarded in lieu of cash, aligning executive compensation with shareholder interests
  • Clear vesting schedule: six monthly earning installments starting 09/01/2025 and two time-based vesting installments on 11/01/2025 and 02/01/2026
  • Transparent disclosure of indirect holdings managed by Armorica Partners, LLC and relationship of reporting person to that entity
Negative
  • None.

Insights

TL;DR: Insider compensation granted as RSUs replaces cash pay and modestly increases potential share-based holdings, appearing routine.

The August 15, 2025 award of 9,727 RSUs to the Chief Commercial Officer in lieu of cash compensation converts cash obligations into equity-based compensation that vests over defined service periods. The award schedule—six monthly earning installments followed by two time-based vesting installments—spreads recognition and aligns retention incentives. Reported direct beneficial ownership of 166,427 shares provides context for the executive's stake but does not in itself indicate a controlling position. This filing is a standard Section 16 disclosure of insider compensation and holdings and is not, on its face, an unusual or immediately material corporate event.

TL;DR: The filing documents routine equity compensation and clarifies indirect holdings through a management vehicle and spouse.

The Form 4 details compensation governance: RSUs awarded under the 2015 Stock Incentive Plan with explicit earning and vesting milestones, tying settlement to continued service. The disclosure that Armorica Partners, LLC manages 32,500 shares and that Mr. Forterre is its managing director and sole shareholder provides required transparency about indirect holdings and voting/dispositive control, while the disclamation of beneficial ownership except for pecuniary interest follows standard practice. Timely filing and signature complete the regulatory obligations.

Gael Forterre, Chief Commercial Officer di VolitionRx Limited (VNRX), ha ricevuto 9.727 unità azionarie soggette a restrizioni (RSU) in data 15 agosto 2025 in sostituzione della retribuzione in contanti. Le RSU saranno corrisposte in azioni al momento della liquidazione e verranno maturate in sei rate mensili approssimativamente uguali a partire dal 1° settembre 2025. Una volta maturate, le RSU resteranno soggette a un ulteriore periodo di vesting basato sul tempo, in due tranche di 4.864 unità il 1° novembre 2025 e 4.863 unità il 1° febbraio 2026, richiedendo la continuazione del servizio per ciascuna data di maturazione e di vesting applicabile.

In seguito all'assegnazione, il Sig. Forterre detiene direttamente 166.427 azioni e possiede indirettamente 5.000 azioni tramite la coniuge e 32.500 azioni gestite da Armorica Partners, LLC, di cui è managing director e unico azionista; egli rinuncia a qualsiasi prelazione di proprietà effettiva fatta eccezione per l'interesse patrimoniale.

Gael Forterre, Chief Commercial Officer de VolitionRx Limited (VNRX), recibió 9.727 unidades de acciones restringidas (RSU) el 15 de agosto de 2025 en lugar de una compensación en efectivo. Las RSU se pagarán en acciones al momento del ajuste y se devengarán en seis cuotas mensuales aproximadamente iguales a partir del 1 de septiembre de 2025. Una vez devengadas, las RSU seguirán sujetas a un período adicional de adquisición basado en el tiempo, en dos cuotas de 4.864 unidades el 1 de noviembre de 2025 y 4.863 unidades el 1 de febrero de 2026, requiriendo la continuidad del servicio para cada fecha de devengo y adquisición aplicable.

Tras la concesión, el Sr. Forterre posee directamente 166.427 acciones e indirectamente 5.000 acciones a través de su cónyuge y 32.500 acciones gestionadas por Armorica Partners, LLC, de la que es director gerente y único accionista; él renuncia a la propiedad beneficiaria salvo por el interés pecuniario.

VolitionRx Limited(VNRX)의 Chief Commercial Officer인 Gael Forterre는 현금 보수 대신 2025년 8월 15일에 9,727개의 제한부 주식 단위(RSU)를 부여받았습니다. RSU는 결제 시 주식으로 지급되며 2025년 9월 1일부터 시작해 약 여섯 번의 동일한 월별 분할로 취득됩니다. 취득된 후에도 RSU는 추가적인 시간 기반 베스팅 대상이며 2025년 11월 1일에 4,864단위, 2026년 2월 1일에 4,863단위의 두 차례로 나뉘어 베스팅되며 각 취득 및 베스팅 날짜에 대해 계속 근무해야 합니다.

수여 이후 Forterre 씨는 직접적으로 166,427주를 보유하고 있으며 배우자를 통해 5,000주를 간접 보유하고, 그가 전무이사이자 유일한 주주인 Armorica Partners, LLC가 관리하는 32,500주를 보유하고 있습니다; 그는 금전적 이익을 제외한 실질적 소유권을 부인합니다.

Gael Forterre, Chief Commercial Officer de VolitionRx Limited (VNRX), s'est vu attribuer 9 727 unités d'actions restreintes (RSU) le 15 août 2025 en lieu et place d'une rémunération en espèces. Les RSU seront réglées en actions à la liquidation et seront acquises en six versements mensuels à peu près égaux à compter du 1er septembre 2025. Une fois acquises, elles resteront soumises à un vesting supplémentaire fondé sur le temps, en deux tranches de 4 864 unités le 1er novembre 2025 et 4 863 unités le 1er février 2026, et requièrent la poursuite du service pour chaque date d'acquisition et de vesting applicable.

Après l'attribution, M. Forterre détient directement 166 427 actions et détient indirectement 5 000 actions par l'intermédiaire de son conjoint et 32 500 actions gérées par Armorica Partners, LLC, dont il est le directeur général et l'unique actionnaire ; il décline toute qualité de propriétaire bénéficiaire, sauf pour l'intérêt pécuniaire.

Gael Forterre, Chief Commercial Officer von VolitionRx Limited (VNRX), wurde am 15. August 2025 statt einer Barvergütung 9.727 Restricted Stock Units (RSUs) zugeteilt. Die RSUs werden bei Abwicklung in Aktien ausgezahlt und werden in sechs annähernd gleichen monatlichen Raten ab dem 1. September 2025 verdient. Nach dem Erwerb unterliegen die RSUs weiterhin einer zeitlich gestaffelten Vesting-Regelung in zwei Tranchen von 4.864 Einheiten am 1. November 2025 und 4.863 Einheiten am 1. Februar 2026 und setzen für jedes relevante Earn- und Vesting-Datum fortgesetzte Dienstleistung voraus.

Nach der Zuteilung besitzt Herr Forterre direkt 166.427 Aktien und hält indirekt 5.000 Aktien über seine Ehefrau sowie 32.500 Aktien, die von Armorica Partners, LLC verwaltet werden, deren Geschäftsführer und Alleingesellschafter er ist; er weist eine nennenswerte wirtschaftliche Eigentümerschaft außer seinem geldwerten Interesse zurück.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Forterre Gael

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2025 A 9,727(1) A $0 166,427 D
Common Stock 5,000 I By Spouse
Common Stock 32,500 I By Armorica Partners, LLC(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On August 15, 2025, the reporting person was awarded 9,727 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 4,864 units and 4,863 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.
2. These shares of common stock are managed by Armorica Partners, LLC (formerly Armori Capital Management, LLC) ("Armorica Partners"). Mr. Forterre is the managing director and sole shareholder of Armorica Partners and has voting and dispositive control over the shares held by Armorica Partners. Mr. Forterre disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Remarks:
/s/ Gael Forterre 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gael Forterre report on Form 4 for VNRX?

The filing reports an award of 9,727 RSUs on 08/15/2025 granted in lieu of cash compensation and discloses direct and indirect shareholdings.

When do the RSUs for VNRX vest and settle?

RSUs are earned in six approximately equal monthly installments beginning 09/01/2025, then subject to additional vesting of 4,864 units on 11/01/2025 and 4,863 units on 02/01/2026.

How many VNRX shares does Gael Forterre beneficially own after the transaction?

The filing reports 166,427 shares beneficially owned following the reported transaction, plus 5,000 indirectly by spouse and 32,500 managed by Armorica Partners, LLC.

What is Armorica Partners' relationship to the reporting person in the VNRX Form 4?

Armorica Partners, LLC is managed by Mr. Forterre; he is the managing director and sole shareholder and has voting and dispositive control over the 32,500 shares it manages.

Was the Form 4 for VNRX filed on time and signed?

Yes; the form includes the reporting person’s signature dated 08/19/2025.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

71.03M
85.20M
17.76%
22.29%
0.18%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON